These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35660221)

  • 1. Identifying key risk factors for premature discontinuation of opioid use disorder treatment in the United States: A predictive modeling study.
    Stafford C; Marrero WJ; Naumann RB; Lich KH; Wakeman S; Jalali MS
    Drug Alcohol Depend; 2022 Aug; 237():109507. PubMed ID: 35660221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals.
    Al Faysal J; Noor-E-Alam M; Young GJ; Lo-Ciganic WH; Goodin AJ; Huang JL; Wilson DL; Park TW; Hasan MM
    Comput Biol Med; 2024 Jul; 177():108493. PubMed ID: 38833799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.
    Choi S; Healy S; Shapoval L; Forthal S; Neighbors CJ
    Subst Use Misuse; 2021; 56(2):258-263. PubMed ID: 33345680
    [No Abstract]   [Full Text] [Related]  

  • 12. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
    Andraka-Christou B
    Health Aff (Millwood); 2021 Jun; 40(6):920-927. PubMed ID: 34097509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors associated with buprenorphine versus methadone use in pregnancy.
    Krans EE; Bogen D; Richardson G; Park SY; Dunn SL; Day N
    Subst Abus; 2016; 37(4):550-557. PubMed ID: 26914546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
    Boudreau DM; Lapham G; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Campbell CI; Rossom RC; Binswanger IA; Yarborough BJ; Arnsten JH; Cunningham CO; Glass JE; Murphy MT; Zare M; Hechter RC; Ahmedani B; Braciszewski JM; Horigian VE; Szapocznik J; Samet JH; Saxon AJ; Schwartz RP; Bradley KA
    J Subst Abuse Treat; 2020 Mar; 112S():41-48. PubMed ID: 32220410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a cascade of care for opioid use disorder among individuals in jail.
    Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
    J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal assessment of sleep in men and women during treatment for opioid use disorder.
    Finan PH; Mun CJ; Epstein DH; Kowalczyk WJ; Phillips KA; Agage D; Smith MT; Preston KL
    Drug Alcohol Depend; 2020 Feb; 207():107698. PubMed ID: 31816489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparative Effectiveness Study on Opioid Use Disorder Prediction Using Artificial Intelligence and Existing Risk Models.
    Fouladvand S; Talbert J; Dwoskin LP; Bush H; Meadows AL; Peterson LE; Mishra YR; Roggenkamp SK; Wang F; Kavuluru R; Chen J
    IEEE J Biomed Health Inform; 2023 Jul; 27(7):3589-3598. PubMed ID: 37037255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.